Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.

被引：0
|
作者：
Celis, Juan Jose [1 ]
Rodriguez, Vanessa [1 ]
Rodriguez, Crismar [1 ]
机构：
[1] Soc Anticancerosa Venezuela, Caracas, Venezuela
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [41] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [42] Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
    Jagosky, Megan
    Tan, Antoinette R.
    BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 393 - 407
  • [43] PERTUZUMAB PLUS TRASTUZUMAB ON THE NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER: A COST ANALYSIS OF RECURRENT DISEASE ON THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Kashiura, D.
    Puopolo, G. R.
    Carmo, L.
    Leme-Souza, R.
    VALUE IN HEALTH, 2019, 22 : S81 - S81
  • [44] Role of pertuzumab in the treatment of HER2-positive breast cancer
    Hubalek, Michael
    Brantner, Christine
    Marth, Christian
    BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 65 - 73
  • [45] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [46] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
    Dang, Chau
    Ewer, Michael S.
    Delaloge, Suzette
    Ferrero, Jean-Marc
    Colomer, Ramon
    de la Cruz-Merino, Luis
    Werner, Theresa L.
    Dadswell, Katherine
    Verrill, Mark
    Eiger, Daniel
    Sarkar, Sriparna
    de Haas, Sanne Lysbet
    Restuccia, Eleonora
    Swain, Sandra M.
    CANCERS, 2022, 14 (11)
  • [47] Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
    Ewer, Michael
    Baselga, Jose
    Clark, Emma
    Benyunes, Mark
    Ross, Graham
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
    Amiri-Kordestani, Laleh
    Wedam, Suparna
    Zhang, Lijun
    Tang, Shenghui
    Tilley, Amy
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    Cortazar, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (21) : 5359 - 5364
  • [49] Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study
    Gianni, L.
    Bisagni, G.
    Colleoni, M.
    Del Mastro, L.
    Zamagni, C.
    Mansutti, M.
    Zambetti, M.
    Frassoldati, A.
    De Fato, R.
    Valagussa, P.
    Viale, G.
    CANCER RESEARCH, 2017, 77
  • [50] Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
    Gianni, Luca
    Colleoni, Marco
    Bisagni, Giancarlo
    Mansutti, Mauro
    Zamagni, Claudio
    Del Mastro, Lucia
    Zambelli, Stefania
    Frassoldati, Antonio
    Barlera, Simona
    Valagussa, Pinuccia
    Viale, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345